You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Rifampin in the Treatment of Leprosy
Ward E. Bullock
Reviews of Infectious Diseases
Vol. 5, Supplement 3. The Use of Rifampin in the Treatment of Nontuberculous Infections (Jul. - Aug., 1983), pp. S606-S613
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4453174
Page Count: 8
Preview not available
The minimal inhibitory concentration of rifampin for Mycobacterium leprae is <1 μg/ml. Therapy with rifampin has proved efficacious both in mice experimentally infected with M. leprae and in humans with leprosy. Rifampin kills M. leprae more rapidly than do other antileprosy drugs currently available. Consequently, M. leprae bacilli from patients with lepromatous disease are rendered noninfectious within three weeks after the institution of rifampin therapy, as determined in the mouse footpad test system. Administration of this antibiotic substantially reduces the quantities of M. leprae discharged in the nasal secretions of lepromatous patients within three weeks, thus rapidly decreasing the potential infectivity of these individuals. Intermittent rifampin therapy for leprosy has been successful, with a low incidence of adverse reactions to the drug. Worldwide, the prevalence of primary and secondary resistance of M. leprae to dapsone has increased markedly. Therefore, the World Health Organization recommends a multidrug regimen that includes intermittent administration of rifampin for the treatment of leprosy.
Reviews of Infectious Diseases © 1983 Oxford University Press